Stockscreener 앱 받기
1,010.31
0.41%
-4.18
시간 외 거래:
1014.40
4.09
+0.40%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment - Reuters
Eli Lilly (LLY) Reports Positive Results from Jaypirca Phase 3 T - GuruFocus
Eli Lilly announces Phase 3 BRUIN CLL-314 met primary endpoint - TipRanks
Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica - Investing News Network
Lilly’s Jaypirca shows higher response rate than Imbruvica in leukemia study By Investing.com - Investing.com South Africa
Lilly’s Jaypirca shows higher response rate than Imbruvica in leukemia study - Investing.com Canada
Lilly's Jaypirca met primary endpoint in head-to-head phase 3 study versus Imbruvica - marketscreener.com
At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma - BioPharma Dive
How Eli Lilly is Tackling Health Literacy and Sustainability - Healthcare Digital
Eli Lilly, Pfizer land on China’s first private insurance list - BusinessLine
Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog - marketscreener.com
Eli Lilly, Pfizer Land on China’s First Private Insurance List - Bloomberg.com
Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip? - MSN
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - AOL.com
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - The Motley Fool
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Is It Too Late To Consider Eli Lilly After Its Massive Multi Year Share Price Surge - simplywall.st
Eli Lilly Among 4 Medical Newcomers To IBD Top Growth Stock Lists - Investor's Business Daily
With Eli Lilly Stock Sliding, Have You Assessed The Risk? - Trefis
Eli Lilly shares fell for seven consecutive sessions - MSN
A look into Eli Lilly’s sustainability efforts and what it suggests about the trend in Big Pharma - Healthcare Brew
Eli Lilly doctor explains how weight-loss medication Zepbound works - Fox 59
Eli Lilly Stock Hit A New Record High On Its Trump Deal; Is LLY Stock A Buy? - Investor's Business Daily
Eli Lilly, Indiana University enter $40 million clinical trial agreement - 95.3 MNC
Eli Lilly's Options Frenzy: What You Need to Know - Benzinga
Eli Lilly lowers price of Zepbound single-dose vials - Drug Store News
Eli Lilly and Company: Making Healthcare Accessible For All - Sustainability Magazine
Compounding pharmacy Strive to occupy 350,000 square feet in Mesa while fighting Big Pharma - The Business Journals
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi - The Globe and Mail
Is It Too Late To Consider Eli Lilly After Its Massive Five Year Share Price Surge? - Yahoo Finance
TheWrap, Eli Lilly and Company Toast Dr. Stacy L. Smith With VIP Beverly Hills Dinner | Photos - TheWrap
BMO Capital Maintains Eli Lilly and (LLY) Outperform Recommendation - Nasdaq
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly and Company
IU, Eli Lilly ink partnership for clinical trials - WFYI
Lilly and IU announce $40M partnership to expand clinical trial access - Indianapolis Recorder
Eli Lilly and Company (LLY): A bull case theory - MSN
Eli Lilly and Company (LLY): A Bull Case Theory - Finviz
Lilly, IU sign clinical trial, research agreement worth up to $40M - dailyjournal.net
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock - Yahoo Finance
A deal with Donald Trump is boosting this pharma giant - Investors' Chronicle
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rati - GuruFocus
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Eli Lilly stock price target raised to $1,200 by BMO on obesity drug outlook - Investing.com Canada
Eli Lilly $1 trln value is bet on Coke-like future - Breakingviews
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating - marketscreener.com
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL - Pharmaceutical Business review -
Eli Lilly, IU agree to $40 million agreement to expand clinical trials - IndyStar
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana - Nasdaq
Berenberg Bank Reaffirms Their Hold Rating on Eli Lilly & Co (LLY) - The Globe and Mail
Lilly, Indiana University launch new partnership - WTHR
Eli Lilly, Indiana University launch new partnership - WTHR
Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers - Stocktwits
Lilly Announces Changing The Thread Collection Campaign - InkFreeNews.com
Tag Archives: Changing the Thread Collection - InkFreeNews.com
Lilly and IU partner to enhance clinical trials and treatments for Hoosiers - WISH-TV
Lilly, IU Boost Hoosier Access to Trials, Treatments - Mirage News
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers - News at IU
Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca - CoinCentral
1 reason to buy Eli Lilly hand over fist before the new year - MSN
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca - GuruFocus
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock? - Barchart.com
Morgan Stanley Bullish on Eli Lilly and Company (LLY) - MSN
0.27%
자본화:
|
볼륨(24시간):